Role of protein S in castration-resistant prostate cancer-like cells

Endocrine-Related Cancer

Volumn 23, Issue 8, 2016, Pages 595-607

  Ning, Peng ^a,b   Zhong, Jia Guo ^c   Jiang, Fan ^b   Zhang, Yi ^b   Zhao, Jie ^a   Tian, Feng ^d   Li, Wei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of General Surgery 3rd Hospital of PLA   (China)

^c Department of Radiology   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Apoptosis; Castration resistant prostate cancer; Oxidative stress; Prostate cancer; Protein S

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; BICALUTAMIDE; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN S; SHORT HAIRPIN RNA; TUBULIN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; APOPTOSIS; CELL LINE; CELL MOTION; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; WOUND HEALING;

ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; KALLIKREINS; MALE; MICE, NUDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN S; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; UP-REGULATION; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84989282779     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-16-0126     Document Type: Article

References (36)

1. Adams LK & Ferrington LS 2014 New recommendations in prostate cancer screening and treatment. Journal of the American Academy of Physician Assistants 27 14-20. (doi: 10. 1097/01. jaa. 0000451872. 86566. bf)
2. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, et al. 2014 Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. Journal of Clinical Oncology 32 3436-3448. (doi: 10. 1200/JCO. 2013. 54. 8404)
3. Bitting RL & Armstrong AJ 2013 Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-Related Cancer 20 R83-R99. (doi: 10. 1530/erc-12-0394)
4. Burstyn-Cohen T, Heeb MJ & Lemke G 2009 Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. Journal of Clinical Investigation 119 2942-2953. (doi: 10. 1172/ JCI39325)
5. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH & Li Y 2014 PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death and Disease 5 e1437. (doi: 10. 1038/cddis. 2014. 415)
6. Dahlback B 2007 The tale of protein S and C4b-binding protein, a story of affection. Thrombosis and Haemostasis 98 90-96. (doi: 10. 1160/ TH07-04-0269)
7. Deng T, Zhang Y, Chen Q, Yan K & Han D 2012 Toll-like receptormediated inhibition of Gas6 and ProS expression facilitates inflammatory cytokine production in mouse macrophages. Immunology 135 40-50. (doi: 10. 1111/j. 1365-2567. 2011. 03511. x)
8. Egan A, Dong Y, Zhang H, Qi Y, Balk SP & Sartor O 2014 Castrationresistant prostate cancer: Adaptive responses in the androgen axis. Cancer Treatment Reviews 40 426-433. (doi: 10. 1016/j. ctrv. 2013. 09. 011)
9. Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A & Pili R 2013 Combinatorial antitumor effect of HDAC and the PI3KAkt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget 4 2225-2236. (doi: 10. 18632/oncotarget)
10. Fernandez JA, Heeb MJ, Xu X, Singh I, Zlokovic BV & Griffin JH 2009 Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica 94 1721-1731. (doi: 10. 3324/ haematol. 2009. 009233)
11. Fisher KW, Montironi R, Lopez Beltran A, Moch H, Wang L, Scarpelli M, Williamson SR, Koch MO & Cheng L 2015 Molecular foundations for personalized therapy in prostate cancer. Current Drug Targets 16 103-114. (doi: 10. 2174/1389450115666141229154500)
12. Guo H, Barrett TM, Zhong Z, Fernandez JA, Griffin JH, Freeman RS & Zlokovic BV 2011 Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Molecular Neurodegeneration 6 13. (doi: 10. 1186/1750-1326-6-13)
13. Ho HY, Cheng ML, Shiao MS & Chiu DT 2013 Characterization of global metabolic responses of glucose-6-phosphate dehydrogenasedeficient hepatoma cells to diamide-induced oxidative stress. Free Radical Biology and Medicine 54 71-84. (doi: 10. 1016/ j. freeradbiomed. 2012. 10. 557)
14. Huppi K, Martin SE & Caplen NJ 2005 Defining and assaying RNAi in mammalian cells. Molecular Cell 17 1-10. (doi: 10. 1016/ j. molcel. 2004. 12. 017)
15. Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N & Aoki Y 2010 Establishment and characterization of an androgen receptordependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate 70 457-466. (doi: 10. 1002/pros. 21079)
16. Kaarbo M, Mikkelsen OL, Malerod L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM & Saatcioglu F 2010 PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cellular Oncology 32 11-27. (doi: 10. 3233/CLO-2009-0487)
17. Karzai FH, Madan RA & Figg WD 2015 Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. Southern Medical Journal 108 224-228. (doi: 10. 14423/SMJ. 0000000000000266)
18. Kumar RC & Thakur MK 2004 Androgen receptor mRNA is inversely regulated by testosterone and estradiol in adult mouse brain. Neurobiology of Aging 25 925-933. (doi: 10. 1016/ j. neurobiolaging. 2003. 10. 011)
19. Kung HJ 2011 Targeting tyrosine kinases and autophagy in prostate cancer. Hormones and Cancer 2 38-46. (doi: 10. 1007/ s12672-010-0053-3)
20. Li W, Bao W, Ma J, Liu X, Xu R, Wang RA & Zhang Y 2008a Metastasis tumor antigen 1 is involved in the resistance to heat stress-induced testicular apoptosis. FEBS Letters 582 869-873. (doi: 10. 1016/ j. febslet. 2008. 02. 013)
21. Li W, Zhu H, Bao W, Fu H, Li Z, Liu X, Xu R, Zhao J & Zhang Y 2008b Involvement of metastasis tumor antigen 1 in hepatic regeneration and proliferation. Cellular Physiology and Biochemistry 22 315-326. (doi: 10. 1159/000149810)
22. Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ & Brodie AM 2000 Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Research 60 6630-6640.
23. Nishikawa M, Miyake H & Fujisawa M 2015 Enhanced sensitivity to sunitinib by inhibition of Akt1 expression in human castrationresistant prostate cancer PC3 cells both in vitro and in vivo. Urology 85 1215. e1-1215. e7. (doi: 10. 1016/j. urology. 2015. 02. 016)
24. Recarte-Pelz P, Tassies D, Espinosa G, Hurtado B, Sala N, Cervera R, Reverter JC & de Frutos PG 2013 Vitamin K-dependent proteins GAS6 and protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. Arthritis Research and Therapy 15 R41. (doi: 10. 1186/ ar4199)
25. Saraon P, Musrap N, Cretu D, Karagiannis GS, Batruch I, Smith C, Drabovich AP, Trudel D, van der Kwast T, Morrissey C, et al. 2012 Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer. Journal of Biological Chemistry 287 34019-34031. (doi: 10. 1074/jbc. M112. 384438)
26. Shiota M, Yokomizo A & Naito S 2011 Oxidative stress and androgen receptor signaling in the development and progression of castrationresistant prostate cancer. Free Radical Biology and Medicine 51 1320-1328. (doi: 10. 1016/j. freeradbiomed. 2011. 07. 011)
27. Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME & Zoubeidi A 2015 Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget 6 9086-9098. (doi: 10. 18632/oncotarget)
28. Suzman DL & Antonarakis ES 2014 Castration-resistant prostate cancer: latest evidence and therapeutic implications. Therapeutic Advances in Medical Oncology 6 167-179. (doi: 10. 1177/1758834014529176)
29. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, et al. 2013 A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urologic Oncology 31 82-86. (doi: 10. 1016/j. urolonc. 2010. 09. 018)
30. Wyatt AW & Gleave ME 2015 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Molecular Medicine 7 878-894. (doi: 10. 15252/emmm. 201303701)
31. Yan L, Xing Z, Guo Z, Fang Z, Jiao W, Guo X, Xu Z, Holmberg A, Nilsson S & Liu Z 2013 Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy. PLoS ONE 8 e55790. (doi: 10. 1371/journal. pone. 0055790)
32. Yu L, Su YS, Zhao J, Wang H & Li W 2013 Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells. FEBS Letters 587 2542-2551. (doi: 10. 1016/ j. febslet. 2013. 06. 029)
33. Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, et al. 2014 Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. Oncogenesis 3 e115. (doi: 10. 1038/ oncsis. 2014. 30)
34. Zhang L, Yang BX, Zhang HT, Wang JG, Wang HL & Zhao XJ 2011 Prostate cancer: An emerging threat to the health of aging men in Asia. Asian Journal of Andrology 13 574-578. (doi: 10. 1038/aja. 2010. 126)
35. Zhang C, Lai JH, Hu B, Zhang S, Zhao J & Li W 2014a A chromatin modifier regulates Sertoli cell response to mono-(2-ethylhexyl) phthalate (MEHP) via tissue inhibitor of metalloproteinase 2 (TIMP2) signaling. Biochimica et Biophysica Acta 1839 1170-1182. (doi: 10. 1016/j. bbagrm. 2014. 08. 006)
36. Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T & Liu X 2014b Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Research 74 6635-6647. (doi: 10. 1158/0008-5472. can-14-1916)